Application for clinical approval of Tianjin International Biomedical Joint Research Institute and Furen Pharmaceutical Co., Ltd. "special project for anti cancer of p-tetrabenzoamide"

The research and development project of "anti-cancer project of p-tetrabenzamide" jointly carried out by Tianjin International Biomedical Joint Research Institute and Furen Pharmaceutical Co., Ltd has completed the stage of animal experiment and formally applied for clinical approval, which is expected to be completed within this year The project is based on the joint molecular cell screening model of the joint research institute Through large-scale in vitro research and animal experiments, it is found that tetracyclines can inhibit a variety of malignant tumors, its efficacy depends on the malignancy of the tumor, and unlike chemotherapy drugs, it will produce excessive side effects on the body, with high efficiency and low toxicity In cooperation with Furen Pharmaceutical Group, the joint research institute will innovate and develop doxycycline's anti-tumor effect, and provide cheap, safe and less side-effect anti-tumor angiogenesis and anti metastasis drugs for clinical tumor patients.